According to these results, we established a novel nomogram based on the mutation of FGFR4, TMB level, PD-L1 expression, and other clinicopathological parameters for advanced non-small cell lung cancer patients with immune checkpoint inhibitors. Here, CD274 is linked to non-small cell lung carcinoma.